1
|
Shapiro J, van Lanschot JJB, Hulshof MCCM,
van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven
HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al:
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for
oesophageal or junctional cancer (CROSS): Long-term results of a
randomised controlled trial. Lancet Oncol. 16:1090–1098.
2015.PubMed/NCBI View Article : Google Scholar
|
2
|
Herskovic A, Martz K, Al-Sarraf M,
Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis
L, Emami B, et al: Combined chemotherapy and radiotherapy compared
with radiotherapy alone in patients with cancer of the esophagus. N
Engl J Med. 326:1593–1598. 1992.PubMed/NCBI View Article : Google Scholar
|
3
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002.PubMed/NCBI View Article : Google Scholar
|
4
|
Obermannová R, Alsina M, Cervantes A,
Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A and Smyth
EC: ESMO Guidelines Committee. Electronic address: simpleclinicalguidelines@esmo.org.
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis,
treatment and follow-up. Ann Oncol. 33:992–1004. 2022.PubMed/NCBI View Article : Google Scholar
|
5
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012.PubMed/NCBI View Article : Google Scholar
|
6
|
Nishimura Y, Jingu K, Itasaka S, Negoro Y,
Murakami Y, Karasawa K, Kawaguchi G, Isohashi F, Kobayashi M, Itoh
Y and Ariga T: Clinical outcomes of radiotherapy for esophageal
cancer between 2004 and 2008: the second survey of the Japanese
Radiation Oncology Study Group (JROSG). Int J Clin Oncol. 21:88–94.
2016.PubMed/NCBI View Article : Google Scholar
|
7
|
Minashi K, Nihei K, Mizusawa J, Takizawa
K, Yano T, Ezoe Y, Tsuchida T, Ono H, Iizuka T, Hanaoka N, et al:
Efficacy of endoscopic resection and selective chemoradiotherapy
for stage I esophageal squamous cell carcinoma. Gastroenterology.
157:382–390. 2019.PubMed/NCBI View Article : Google Scholar
|
8
|
Suzuki T, Okamura A, Watanabe M, Mine S,
Imamura Y, Asari T, Osumi H, Nakayama I, Ichimura T, Ogura M, et
al: Neoadjuvant chemoradiotherapy with cisplatin plus fluorouracil
for borderline resectable esophageal squamous cell carcinoma. Ann
Surg Oncol. 27:1510–1517. 2020.PubMed/NCBI View Article : Google Scholar
|
9
|
Kato K, Ito Y, Nozaki I, Daiko H, Kojima
T, Yano M, Ueno M, Nakagawa S, Takagi M, Tsunoda S, et al:
Parallel-group controlled trial of surgery versus chemoradiotherapy
in patients with stage I esophageal squamous cell carcinoma.
Gastroenterology. 161:1878–1886. 2021.PubMed/NCBI View Article : Google Scholar
|
10
|
Ishida K, Ando N, Yamamoto S, Ide H and
Shinoda M: Phase II study of cisplatin and 5-fluorouracil with
concurrent radiotherapy in advanced squamous cell carcinoma of the
esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical
Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 34:615–619.
2004.PubMed/NCBI View Article : Google Scholar
|
11
|
Sugimura K, Miyata H, Tanaka K, Makino T,
Takeno A, Shiraishi O, Motoori M, Yamasaki M, Kimura Y, Hirao M, et
al: Multicenter randomized phase 2 trial comparing
chemoradiotherapy and docetaxel plus 5-fluorouracil and cisplatin
chemotherapy as initial induction therapy for subsequent conversion
surgery in patients with clinical T4b esophageal cancer: Short-term
Results. Ann Surg. 274:e465–e472. 2021.PubMed/NCBI View Article : Google Scholar
|
12
|
Takeuchi H, Ito Y, Machida R, Kato K,
Onozawa M, Minashi K, Yano T, Nakamura K, Tsushima T, Hara H, et
al: A Single-Arm confirmatory study of definitive chemoradiation
therapy including salvage treatment for clinical stage II/III
esophageal squamous cell carcinoma (JCOG0909 Study). Int J Radiat
Oncol Biol Phys. 114:454–462. 2022.PubMed/NCBI View Article : Google Scholar
|
13
|
Cockcroft DW and Gault MH: Prediction of
creatinine clearance from serum creatinine. Nephron. 16:31–41.
1976.PubMed/NCBI View Article : Google Scholar
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
15
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM classification of malignant tumours. John Wiley
& Sons, 2017.
|
16
|
Clavien PA, Barkun J, de Oliveira ML,
Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J,
Slankamenac K, Bassi C, et al: The Clavien-Dindo classification of
surgical complications: Five-year experience. Ann Surg.
250:187–196. 2009.PubMed/NCBI View Article : Google Scholar
|
17
|
Japan Esophageal S: Japanese
classification of esophageal cancer, 11th Edition: Part I.
Esophagus. 14:1–36. 2017.PubMed/NCBI View Article : Google Scholar
|